drugset
drugset / Trial / NCT01536002

Pharmacokinetics of Propofol in Morbidly Obese Patients

NCT01536002 ↗

Phase 4 Completed 69 enrolled Oslo University Hospital
NaSingle-groupOpen-labelDiagnostic

Summary

The objectives of this study are * To determine PK of propofol in bariatric patients * To identify the physiological variables that induce propofol PK changes in bariatric patients, when compared to a normal-weight population. * To define context-sensitive half-time profiles for propofol in bariatric patients.

Timeline

Start
2011-06-07
Primary completion
2014-05-07
Completion
2014-05-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Propofol Small molecule 3 mg/kg Intravenous
Subject Propofol Small molecule 4 mg/kg Intravenous

Indications

morbid obesity